Form 4: Ideaya Biosciences Director Acquires Stock Options

Director Jeffrey Stein acquired stock options in Ideaya Biosciences, Inc. on May 31, 2024.

Summary

• On May 31, 2024, Jeffrey Stein, a director of Ideaya Biosciences, Inc., acquired stock options.
• The transaction involved the acquisition of 16,200 stock options with an exercise price of $36.55.
• These options vest on the earlier of the first anniversary of the grant date or immediately prior to the next Annual Meeting, contingent upon continued service on the Board.
• Following the transaction, Stein directly owns 16,200 derivative securities.

Sentiment

Score: 7

Explanation: The document reflects a routine transaction (stock option grant) for a director, which is generally viewed neutrally to positively as it aligns the director's interests with the company's performance.

Industry Context

This is a standard Form 4 filing, reflecting a director's acquisition of stock options, a common practice in executive compensation within the biotechnology industry.

Comparison to Industry Standards

• Stock option grants are a typical component of compensation packages for directors and executives in biotech companies like Ideaya Biosciences.
• Companies such as Amgen, Gilead Sciences, and Regeneron Pharmaceuticals also utilize stock options as part of their executive compensation plans.
• The vesting schedule and exercise price are generally aligned with industry norms to incentivize long-term performance and alignment with shareholder interests.

Key Dates